13F Holdings
中文EN

BLSM BlossomHill Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1839970 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets33.9%
Debt / equity—
Current ratio5.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302025Q32025-09-302025Q22025-06-30
Income statement
Revenue————
R&D expense$21.93M$21.36M$14.67M$12.53M
SG&A expense$3.55M$3.31M$2.06M$1.57M
Operating income-$25.48M-$24.67M-$16.73M-$14.10M
Net income-$24.01M-$23.76M-$15.98M-$13.24M
EBITDA-$25.36M—-$16.63M—
EPS (basic)-1.29-8.75-6.54-5.51
EPS (diluted)-1.29-8.75-6.54-5.51
Weighted avg. shares (diluted)18.56M2.71M2.44M2.41M
Balance sheet
Cash & equivalents$224.90M$95.38M$67.81M$79.11M
Current assets—$100.97M——
PP&E, net—$1.49M——
Total assets—$124.13M——
Current liabilities—$18.62M——
Total liabilities—$42.09M——
Shareholders' equity$211.08M-$174.78M-$111.43M-$96.03M
Shares outstanding—2.55M——
Cash flow statement
Operating cash flow-$22.19M—-$11.58M—
Capital expenditure$0—$22,000—
Free cash flow-$22.19M—-$11.60M—
Investing cash flow$0—-$22,000—
Financing cash flow$151.72M—$302,000—
Depreciation & amortization$123,000—$97,000—
Stock-based compensation$1.19M—$276,000—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.